...
首页> 外文期刊>Canadian Journal of Physiology and Pharmacology >Cardioprotection against myocardial reperfusion injury: Successes, failures, and perspectives
【24h】

Cardioprotection against myocardial reperfusion injury: Successes, failures, and perspectives

机译:防止心肌再灌注损伤的心脏保护:成功,失败和观点

获取原文
获取原文并翻译 | 示例
           

摘要

The past few decades have witnessed an enormous number of research strategies aimed at protecting the heart against myocardial ischemia-reperfusion injury. Several randomized clinical trials are nowadays in progress testing whether promising therapeutic strategies aimed at preventing lethal reperfusion injury can be translated from bench to bedside. Many of these interventions, either pharmacological or mechanical, are targeting mitochondria as the final effectors of cardioprotection. Despite encouraging pre-clinical studies and small proof of concept clinical trials, there are still several limitations that may jeopardize the efficacy of cardioprotective strategies. These limitations include clinical setting, patient profile, drug administration, and methods for evaluating treatment efficacy. Identifying potential mechanistic and methodological pitfalls in the field may improve future translational research.
机译:在过去的几十年中,目睹了众多旨在保护心脏免受心肌缺血-再灌注损伤的研究策略。如今,正在进行一些随机临床试验,以测试旨在防止致死性再灌注损伤的有前途的治疗策略是否可以从实验台转化为床旁。这些干预措施中的许多,无论是药理的还是机械的,都将线粒体作为心脏保护的最终效应物。尽管令人鼓舞的临床前研究和少量的概念验证临床试验,但仍有一些局限性可能会危害心脏保护策略的有效性。这些局限性包括临床环境,患者概况,药物给药以及评估治疗效果的方法。确定该领域潜在的机械和方法上的陷阱可能会改善未来的翻译研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号